Disruptive effects of the prototypical cannabinoid Δ9- tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats

Behavioural Pharmacology

Volumn 22, Issue 3, 2011, Pages 191-202

  Sokolic, Ljiljana ^a   Long, Leonora E ^c   Hunt, Glenn E ^a   Arnold, Jonathon C ^b   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Pharmacology ^*  (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

9 tetrahydrocannabinol; auditory learning; cannabinoid; fatty acid amide hydrolase inhibition; olfactory learning; rat; URB 597

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; RIMONABANT; TETRAHYDROCANNABINOL; WATER;

ANIMAL EXPERIMENT; ARTICLE; AUDITORY DISCRIMINATION; COGNITION; CONTROLLED STUDY; LEARNING; LEMON; MALE; NONHUMAN; OLFACTORY DISCRIMINATION; OLFACTORY REVERSAL LEARNING; PERCEPTION; RAT; REWARD; SENSITIVITY ANALYSIS; SMELLING; STRAWBERRY; TASK PERFORMANCE; THIRST;

ANIMALS; BENZAMIDES; CARBAMATES; DISCRIMINATION LEARNING; HEARING; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; REVERSAL LEARNING; SMELL; TETRAHYDROCANNABINOL;

EID: 79955427915     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328345c82b     Document Type: Article

References (83)

1. Ashton CH (2001). Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101-106. (Pubitemid 32158071)
2. Boggan WO, Steele RA, Freedman DX (1973). 9 -Tetrahydrocannabinol effect on audiogenic seizure susceptibility. Psychopharmacologia 29:101-106.
3. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103-1110. (Pubitemid 350029716)
4. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T (2007). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of delta 9-tetrahydrocannabinol. Psychopharmacology (Berl) 192: 325-336. (Pubitemid 46705399)
5. Boucher AA, Vivier L, Metna-Laurent M, Brayda-Bruno L, Mons N, Arnold JC, Micheau J (2009). Chronic treatment with delta (9)-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain. Behav Pharmacol 20:45-55.
6. Boucher AA, Hunt GE, Micheau J, Huang XF, McGregor IS, Karl T, Arnold JC (2011). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 12:1-13.
7. Clapper JR, Mangieri RA, Piomelli D (2009). The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56:235-243.
8. Conrad DG, Elsmore TF, Sodetz FJ (1972). 9 -tetrahydrocannabinol: dose-related effects on timing behavior in chimpanzee. Science 175:547-550.
9. Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA (2007). Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) 190:135-143. (Pubitemid 46011174)
10. D'Souza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259: 413-431.
11. Darmani NA, Pandya DK (2000). Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 107:931-945.
12. Deadwyler SA, Goonawardena AV, Hampson RE (2007). Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes. Behav Pharmacol 18:571-580. (Pubitemid 47356383)
13. Egerton A, Brett RR, Pratt JA (2005). Acute delta 9-tetrahydrocannabinol- induced deficits in reversal learning: neural correlates of affective inflexibility. Neuropsychopharmacology 30:1895-1905. (Pubitemid 41486414)
14. Egerton A, Allison C, Brett RR, Pratt JA (2006). Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 30:680-695.
15. El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, et al. (2010). Antidepressant-like effect of delta 9-tetrahydrocannabinol and other canna-binoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 95:434-442.
16. Elsmore TF (1972). Effects of delta-9-tetrahydrocannabinol on temporal and auditory discrimination performances of monkeys. Psychopharmacologia 26:62-72.
17. Fachner J (2006). An ethno-methodological approach to cannabis and music perception, with EEG brain mapping in a naturalistic setting. Anthropol Conscious 17:78-103.
18. Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V (2009). The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol 85:57-72.
19. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620-18625. (Pubitemid 43011275)
20. Gunasekaran N, Long LE, Dawson BL, Hansen GH, Richardson DP, Li KM, et al. (2009). Reintoxication: the release of fat-stored delta (9)- tetrahydrocannabi-nol (THC) into blood is enhanced by food deprivation or ACTH exposure. Br J Pharmacol 158:1330-1337.
21. Hajos M, Hoffmann WE, Kocsis B (2008). Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 63:1075-1083.
22. Haller VL, Cichewicz DL, Welch SP (2006). Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 546:60-68. (Pubitemid 44348895)
23. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV, Goldberg S (2009). Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204:607-616.
24. Hampson RE, Deadwyler SA (2000). Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 20:8932-8942.
25. Holtzman D, Lovell RA, Jaffe JH, Freedman DX (1969). 1-delta 9-tetrahydro-cannabinol: neurochemical and behavioral effects in the mouse. Science 163:1464-1467.
26. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47:345-358. (Pubitemid 39298276)
27. Iversen L (2003). Cannabis and the brain. Brain 126:1252-1270. (Pubitemid 36644373)
28. Iversen L (2005). Long-term effects of exposure to cannabis. Curr Opin Pharmacol 5:69-72. (Pubitemid 40124537)
29. Jarbe TU, Andrzejewski ME, DiPatrizio NV (2002). Interactions between the CB1 receptor agonist delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911-919. (Pubitemid 35246241)
30. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81. (Pubitemid 36098263)
31. Kedzior KK, Martin-Iverson MT (2006). Chronic cannabis use is associated with attention-modulated reduction in prepulse inhibition of the startle reflex in healthy humans. J Psychopharmacol 20:471-484. (Pubitemid 43875177)
32. Kempel P, Lampe K, Parnefjord R, Hennig J, Kunert HJ (2003). Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiology 48:95-101. (Pubitemid 37176874)
33. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970). Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 170:1320-1322.
34. Mahler SV, Smith KS, Berridge KC (2007). Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32:2267-2278. (Pubitemid 47587687)
35. Mallet PE, Beninger RJ (1998). The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta 9-tetrahydrocannabinol or anandamide. Psychopharmacology (Berl) 140: 11-19. (Pubitemid 28524302)
36. Malone DT, Taylor DA (2006). The effect of Delta 9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav Brain Res 166:101-109. (Pubitemid 41677366)
37. Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G, et al. (2009). Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16:332-337.
38. McGregor IS (1996). Using Strawberry Tree Workbench Mac and Workbench PC software for data acquisition and control in the animal learning laboratory. Behav Res Methods Instrum Comput 28:38-48.
39. McGregor IS, Dam KD, Mallet PE, Gallate JE (2005). Delta 9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. Alcohol Alcohol 40:35-45.
40. Moskowitz H (1974). Effects of marihuana on auditory signal detection. Psychopharmacologia 40:137-145.
41. Niyuhire F, Varvel SA, Thorpe AJ, Stokes RJ, Wiley JL, Lichtman AH (2007). The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task specific. Psychopharmacology (Berl) 191:223-231. (Pubitemid 46354610)
42. O'Leary DS, Block RI, Flaum M, Schultz SK, Boles Ponto LL, Watkins GL, et al. (2000). Acute marijuana effects on rCBF and cognition: a PET study. Neuroreport 11:3835-3841.
43. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, et al. (2002). Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26:802-816. (Pubitemid 34455033)
44. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. (2006). Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21-38. (Pubitemid 44133578)
45. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001). Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909-915. (Pubitemid 32937912)
46. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2002). Cognitive measures in long-term cannabis users. J Clin Pharmacol 42:41S-47S. (Pubitemid 35205045)
47. Presburger G, Robinson JK (1999). Spatial signal detection in rats is differentially disrupted by delta-9-tetrahydrocannabinol, scopolamine, and MK-801. Behav Brain Res 99:27-34. (Pubitemid 29084524)
48. Ranganathan M, D'Souza DC (2006). The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188:425-444. (Pubitemid 44498214)
49. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244. (Pubitemid 24268029)
50. Robbe D, Buzsaki G (2009). Alteration of theta timescale dynamics of hippocampal place cells by a cannabinoid is associated with memory impairment. J Neurosci 29:12597-12605.
51. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 9:1526-1533. (Pubitemid 44862661)
52. Robinson L, Goonawardena AV, Pertwee RG, Hampson RE, Riedel G (2007). The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. Br J Pharmacol 151:688-700. (Pubitemid 47016297)
53. Robinson L, Goonawardena AV, Pertwee R, Hampson RE, Platt B, Riedel G (2010). WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. Behav Brain Res 208:584-592.
54. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM (2008). Effects of acute oral delta 9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18:569-577.
55. Roser P, Vollenweider FX, Kawohl W (2010). Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry 11:208-219.
56. Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, et al. (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18:1292-1301. (Pubitemid 351769783)
57. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, et al. (2008). The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54:129-140.
58. Schlosburg JE, Kinsey SG, Lichtman AH (2009). Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 11:39-44.
59. Schneider M, Koch M (2002). The cannabinoid agonist WIN 55 212-2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13:29-37. (Pubitemid 34174529)
60. Schoenbaum G, Shaham Y (2008). The role of orbitofrontal cortex in drug addiction: a review of preclinical studies. Biol Psychiatry 63:256-262.
61. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A (2010). Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsycho-pharmacol 13:373-386.
62. Silva de Melo LC, Cruz AP, Rios Valentim SJ Jr, Marinho AR, Mendonca JB, Nakamura-Palacios EM (2005). Delta (9)-THC administered into the medial prefrontal cortex disrupts the spatial working memory. Psychopharmacology (Berl) 183:54-64. (Pubitemid 41484182)
63. Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O'Donnell BF (2006). Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry 163:1798-1805. (Pubitemid 44522490)
64. Slotnick B (2001). Animal cognition and the rat olfactory system. Trends Cogn Sci 5:216-222. (Pubitemid 32372628)
65. Slotnick BM, Schoonover FW (1984). Olfactory thresholds in unilaterally bulbectomized rats. Chemical Senses 9:325-340. (Pubitemid 15192575)
66. Slotnick BM, Schellinck H (2001). Methods in olfactory research with rodents. In: Simon SA, Nicolelis M, editors. Frontiers and methods in chemosenses. Washington DC: CRC Press. pp. 21-61.
67. Sofuoglu M, Sugarman DE, Carroll KM (2010). Cognitive function as an emerging treatment target for marijuana addiction. Exp Clin Psychopharmacol 18:109-119.
68. Sokolic L, McGregor IS (2007). Benzodiazepines impair the acquisition and reversal of olfactory go/no-go discriminations in rats. Behav Neurosci 121:527-534. (Pubitemid 47445105)
69. Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, et al. (2007). The endogenous cannabinoid anandamide produces delta-9-tetrahydrocan- nabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321:370-380. (Pubitemid 46456957)
70. Solowij N, Battisti R (2008). The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1:81-98.
71. Solowij N, Michie PT, Fox AM (1991). Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40:683-688.
72. Solowij N, Michie PT, Fox AM (1995). Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37:731-739.
73. Takahashi RN, Pamplona FA, Fernandes MS (2005). The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270-275. (Pubitemid 40616094)
74. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fur G, Soubrie P (1996). Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 126:165-172. (Pubitemid 26246767)
75. Trezza V, Vanderschuren LJ (2008). Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl) 197: 217-227.
76. Varvel SA, Hamm RJ, Martin BR, Lichtman AH (2001). Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl) 157:142-150. (Pubitemid 32802125)
77. Varvel SA, Cravatt BF, Engram AE, Lichtman AH (2006). Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J Pharmacol Exp Ther 317:251-257.
78. Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH (2007). Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 32:1032-1041. (Pubitemid 46631982)
79. Varvel SA, Wise LE, Lichtman AH (2009). Are CB1 receptor antagonists nootropic or cognitive impairing agents? Drug Dev Res 70:555-565.
80. Verrico CD, Jentsch JD, Roth RH, Taylor JR (2004). Repeated, intermittent delta (9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention. Neuropsychopharma- cology 29:522-529. (Pubitemid 38365928)
81. Wise LE, Harloe JP, Lichtman AH (2009). Fatty acid amide hydrolase (FAAH) knockout mice exhibit enhanced acquisition of an aversive, but not of an appetitive, Barnes maze task. Neurobiol Learn Mem 92:597-601.
82. Wolff MC, Leander JD (2003). SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol 477:213-217. (Pubitemid 38366393)
83. Yoshida R, Ohkuri T, Jyotaki M, Yasuo T, Horio N, Yasumatsu K, et al. (2010). Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 107:935-939.